Tumor-infiltrating NY-ESO-1–specific CD8 <sup>+</sup> T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki(University of Chicago), Kunle Odunsi(University of Chicago), Shashikant Lele(Memorial Sloan Kettering Cancer Center), Cheryl Eppolito, Amy Beck, Sacha Gnjatic(Tisch Hospital), Takemasa Tsuji(Memorial Sloan Kettering Cancer Center), Paulette Mhawech‐Fauceglia, Lloyd J. Old(Gynecologic Oncology Group), Austin Miller(Roswell Park Comprehensive Cancer Center), Feng Qian(Shanghai Public Health Clinical Center), Protul Shrikant
Cited by 844
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k